By VETTAPHARMA reporter: Bristol Myers Squibb (NYSE: BMY), a global leader in oncology, has entered a collaboration with Microsoft to accelerate the early detection of lung cancer by integrating advanced artificial intelligence (AI) tools into clinical radiology workflows. The partnership will leverage Microsoft’s Precision Imaging Network to deploy U.S. FDA-cleared AI radiology algorithms that automatically analyze X-rays and CT scans, supporting radiologists in identifying lung disease and hard-to-detect lung nodules that may signal early-stage cancer.
Lung cancer remains the leading cause of cancer-related deaths in the United States, with around 125,000 deaths and 227,000 new cases annually. The collaboration aims to expand access to earlier detection and follow-up care, particularly in medically underserved communities, including rural hospitals and community clinics that historically face challenges with screening and guideline-based follow-up.
Under the initiative, AI workflows will be integrated into Microsoft’s radiology solutions, which are already used by more than 80% of U.S. hospitals to share imaging data and access third-party imaging AI tools. These capabilities are expected to help radiologists reduce clinical workload while improving accuracy and timeliness of lung cancer diagnosis.
BMS digital health leadership highlighted the potential of AI-enabled workflows to guide clinicians in identifying patients with non-small cell lung cancer (NSCLC) and connecting them to optimal care pathways and precision therapies. The collaboration also emphasizes health equity, seeking to extend advanced diagnostic technology to populations with limited access to regular screening and follow-up care.
Microsoft executives welcomed the opportunity to use the widely deployed AI-powered radiology platform to assist clinicians in detecting early signs of lung cancer — often before patients show symptoms — and to streamline care pathways, aligning with broader goals to enhance healthcare efficiency and patient outcomes.
Source credit:
- Bristol Myers Squibb. (2026, January 20). Bristol Myers Squibb announces collaboration with Microsoft to advance AI-driven early detection of lung cancer [Press release]. BMS News Center. Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, and peer-reviewed articles for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. The platform and its contributors disclaim any liability for actions taken based on the information presented.
